Skip to main content

Table 1 The expression of MVP and clinicopathologic parameters of patients with lung cancer

From: Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway

 

All patients (n = 120)

Patients with adenocarcinoma (n = 44)

Patients with squamous cell carcinoma (n = 76)

Sum. (%)

Low(%)

High(%)

P

Sum.(%)

Low(%)

High(%)

P

Sum. (%)

Low (%)

High (%)

P

Age (years)

59.4 ± 8.4

59.7 ± 7.9

58.8 ± 9.4

0.55a

57.6 ± 7.9

56.9 ± 7.8

58.8 ± 8.0

0.44a

60.4 ± 8.7

61.4 ± 7.5

58.8 ± 10.2

0.19a

Gender

   

0.66b

   

1.00b

   

0.24b

 Male

92(76.7)

56(60.9)

36(39.1)

 

23(52.3)

15(65.2)

8(34.8)

 

69(90.8)

41(59.4)

28(40.6)

 

 Female

28(23.3)

19(67.9)

9(32.1)

 

21(47.7)

13(61.9)

8(38.1)

 

7(9.0)

6(85.7)

1(14.3)

 

Depth of invasion

   

0.81b

   

0.64b

   

0.56b

 T1/T2

100(83.3)

63(63.0)

37(37.0)

 

39(88.6)

24(61.5)

15(38.5)

 

61(80.3)

39(63.9)

22(36.1)

 

 T3

20(16.7)

12(60.0)

8(40.0)

 

5(11.4)

4(80.0)

1(20.0)

 

15(19.7)

8(53.3)

7(46.7)

 

Lymph node metastasis

   

0.45b

   

0.01b

   

0.48b

 N0

60(50.0)

35(58.3)

25(41.7)

 

24(54.5)

11(45.8)

13(54.2)

 

36(47.4)

24(66.7)

12(33.3)

 

 N1/N2/N3

60(50.0)

40(66.7)

20(33.3)

 

20(45.5)

17(85.0)

3(15.0)

 

40(52.6)

23(57.5)

17(42.5)

 

Distant metastasis

   

1.00b

   

1.00b

   

–

 M0

119(99.0)

74(62.2)

45(37.8)

 

43(97.7)

27(62.8)

16(37.2)

 

76(100.0)

47(61.8)

29(38.2)

 

 M1

1(0.8)

1(100.0)

0(0.0)

 

1(2.3)

1(100.0)

0(0.0)

 

0(0.0)

0(0.0)

0(0.0)

 

TNM stage

   

0.19b

   

0.09b

   

0.94b

 I

40(33.3)

23(57.5)

17(42.5)

 

16(36.4)

8(50.0)

8(50.0)

 

24(31.6)

15(62.5)

9(37.5)

 

 II

65(54.2)

39(60.0)

26(40.0)

 

20(45.5)

12(60.0)

8(40.0)

 

45(59.2)

27(60.0)

18(40.0)

 

 III

14(11.7)

12(85.7)

2(14.3)

 

7(15.8)

7(100.0)

0(0.0)

 

7(9.2)

5(71.4)

2(28.6)

 

 IV

1(0.8)

1(100.0)

0(0.0)

 

1(2.3)

1(100.0)

0(0.0)

 

0(0.0)

0(0.0)

0(0.0)

 

Tumor diameter

4.7 ± 2.2

4.7 ± 2.3

4.6 ± 2.1

0.73 a

4.0 ± 2.0

4.1 ± 2.0

3.7 ± 2.0

0.54 a

5.0 ± 2.2

5.1 ± 2.4

5.0 ± 2.1

0.94 a

Pathology

   

1.00b

   

–

   

–

 Adenocarcinoma

44(36.7)

28(63.6)

16(36.4)

 

–

–

–

 

–

–

–

 

 Squamous cell carcinoma

76(63.3)

47(61.8)

29(38.2)

 

–

–

–

 

–

–

–

 

Mediam survival time (month)

32

31

36

0.26 c

32

25

47

0.04 c

32

35

30

0.84 c

  1. aIndependent sample t test
  2. bFisher exact probability test
  3. cLogrank test